General Federal Contracts — April 08, 2026

Shionogi Inc awarded $119,160,691 cost-plus-fixed-fee contract (potential $481M base + options) by HHS BARDA for antibiotics targeting drug-resistant infections and biothreats, with 10-year performance to 2036-03-10 under full competition.

Salient CRGT Inc received $93,004,285 time-and-materials delivery order (potential $198M) from VA Technology Acquisition Center, with $21.8M already outlayed across 9 subawards for NAICS 541512 IT services through potential 2030.

ManTech Advanced Systems International (parent ManTech International) awarded $77,416,388 cost-plus-award-fee delivery order (potential $909M ceiling) via GSA for cyber IT enterprise services, with 43 subawards totaling $161M and potential to 2032.

Vedanta Biosciences Inc, a small business, received $79,146,088 cost-sharing contract (potential $114M) from HHS BARDA, with $70.7M outlayed for biotech R&D against antibiotic-resistant infections through potential 2031.

IBM's $110,364,715 firm-fixed-price delivery order from Treasury IRS for e-file modernization fully outlayed but terminated for convenience on 3/24/2025 per executive orders, limiting future revenue despite $70M subawards.

Serco Inc awarded $95,794,171 firm-fixed-price order (potential $239M) from Pension Benefit Guaranty Corp, with $55.7M outlayed for customer service improvements via NAICS 541330 through potential 2029.

$116,136,797 cost-plus-award-fee delivery order from GSA FAS (2018-2023) has $59M subawarded across 164 but negative -$162k outlayed, signaling potential completion issues despite potential $165M.

High fixed-price risk on Quality Support Inc's $112.6M State Dept visa support (SDVOSB set-aside) and ENSCO Inc's $69.8M DOT rail inspection, both with $0 or partial outlays amid long periods to 2026+.

11 contracts with $0 outlays (e.g., ManTech $77M GSA, Deloitte $69.7M State Dept, GEO Group $66.9M ICE) expose to funding delays post-award in FY2026.

IBM's $110M Treasury IRS contract terminated 3/24/2025 per executive orders, signaling policy-driven disruptions in IT modernization.

HHS BARDA biotech R&D expansion via Shionogi Inc $119M (to $481M) and Vedanta $79M (to $114M) for biothreat antibiotics, aligning with preparedness priorities.

VA IT services ramp-up with Salient CRGT $93M (to $198M potential to 2030) and Greenbrier Government Solutions $61M software maintenance to 2026.

ManTech's $77M GSA delivery (to $909M ceiling to 2032) for USSOUTHCOM cyber IT signals scalable enterprise wins.

Shionogi Inc's $119M (potential $481M to 2036) and Vedanta Biosciences' $79M (potential $114M, $70M outlayed to 2031) cost-plus contracts under NAICS 541714 fund late-stage antibiotics for drug-resistant pathogens.

Salient CRGT's $93M (potential $198M to 2030, $21M outlayed), Greenbrier's $61M (near-fully outlayed to 2026), and GD IT's $65M (high subawards to 2026) delivery orders emphasize NAICS 541512/541519 for technical apps and software.

IBM's dual awards: $90M ongoing (potential $147M to 2029, $50M outlayed) vs. $110M terminated e-file contracts highlight persistent NAICS 541512 demand but execution volatility.

{"entity"=>"Shionogi Inc", "reason"=>"$119M HHS BARDA obligation with $0 outlayed and potential $481M options over 10 years", "trigger"=>"outlay progress, FDA marketing milestones"}

{"entity"=>"Salient CRGT Inc", "reason"=>"$93M VA IT order with $21.8M outlayed and $198M ceiling to potential 2030-04-10", "trigger"=>"option exercises"}

{"entity"=>"ManTech International Corp", "reason"=>"$77M GSA USSOUTHCOM cyber with $0 outlayed, $909M ceiling, $161M subawards to potential 2032", "trigger"=>"initial outlays, 2026-04-24 option decision"}

{"entity"=>"International Business Machines Corp", "reason"=>"$90M ongoing Treasury IRS MEF vs. $110M terminated e-file order", "trigger"=>"termination settlement, $147M option exercises"}

{"entity"=>"Vedanta Biosciences Inc", "reason"=>"$79M BARDA with $70M outlayed and $35M options to potential 2031-12-31", "trigger"=>"remaining obligation drawdown"}